Literature DB >> 2748946

The influence of cisplatin on the response of mouse kidneys to multifraction irradiation.

F A Stewart1, Y Oussoren, H Bartelink.   

Abstract

The aim of these studies was to measure the extent of renal damage after fractionated irradiation in combination with cis-diamminedichloroplatinum(II) (c-DDP) and to determine whether there was any drug-induced inhibition of repair of sublethal X-ray damage. Fractionated irradiations were given either in a short overall treatment time of 2 days or in a total time of one month, in which irradiations were given in the first and fourth weeks only. A single dose of c-DDP was given before the first X-ray dose for treatments in a total time of 2 days and before the first X-ray dose of each week for the split-course treatments. Renal function was measured at monthly intervals (from 18 to 39 weeks after the start of treatment) by clearance of 51Cr-EDTA. The renal damage was always worse after combined treatments (X + c-DDP) than after X-rays alone. A comparison of radiation dose-response curves with and without c-DDP yielded Dose Enhancement Factors (DEFs) of 1.2 to 1.4 for all fractionation schedules, with no trend for an increase in DEF with increasing number of fractions. A Linear-Quadratic (LQ) analysis of the data demonstrated that there was no change in the alpha/beta value for renal radiation damage for the combined treatments compared with X-rays alone (alpha/beta = 2-3 Gy). These results suggest that the increased renal damage which occurred after combined X + c-DDP was due to independent, additive toxicities and not to radiosensitization or inhibition of X-ray repair by the drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748946     DOI: 10.1016/0167-8140(89)90122-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies.

Authors:  Kilian Salerno May; Gary Y Yang; Nikhil I Khushalani; Rameela Chandrasekhar; Gregory E Wilding; Leayn Flaherty; Harish K Malhotra; Richard C Russo; John C Warner; Johnny C Yap; Renuka V Iyer; Chukwumere E Nwogu; Saikrishna S Yendamuri; John F Gibbs; Hector R Nava; Dominick Lamonica; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-09

2.  Correction of liver dysfunction in DNA repair-deficient mice with an ERCC1 transgene.

Authors:  J Selfridge; K T Hsia; N J Redhead; D W Melton
Journal:  Nucleic Acids Res       Date:  2001-11-15       Impact factor: 16.971

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.